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Abstract
Background: Rheumatoid arthritis fibroblast-like synovial cells (RA-FLS) show resistance to methotrexate (MTX)
treatment. To better understand the mechanisms of this resistance, RA-FLS and osteoarthritis fibroblast-like synovial
cells (OA-FLS) were isolated and exposed to MTX. We analyzed the autophagy induced by MTX in vitro and its
relationship to apoptosis.
Methods: Cell viability was evaluated using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay,
and apoptosis was detected by flow cytometry and Western blot analysis. Autophagy was determined by
transmission electron microscopy as well as Western blot analysis. The expression levels of Beclin-1, LC3, Akt, p-Akt,
mammalian target of rapamycin (mTOR), p-mTOR, high mobility group box chromosomal protein 1 (HMGB1), and
an 85 kDa caspase cleaved fragment of poly(ADP-ribose) polymerase were measured by Western blotting.
Results: MTX-induced apoptosis was increased in OA-FLS compared with RA-FLS. However, MTX stimulated the
autophagy response in RA-FLS by inducing autophagosome formation, but not in OA-FLS. In RA-FLS, transfection
with Beclin-1 small interfering RNA inhibited autophagy and increased susceptibility to MTX, which induces cell
death. MTX upregulated autophagy through its ability to enhance the expression of HMGB1 and Beclin-1 rather
than through the Akt/mTOR pathway.
Conclusions: Autophagy induction contributes to resistance to MTX treatment in fibroblasts from patients with
rheumatoid arthritis.
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Background
With a high prevalence and an associated level of
disability, rheumatoid arthritis (RA) is the most common
serious autoimmune disease in several parts of the
world. To date, it is widely accepted that both the
inflammatory and destructive features of RA are driven
by synovitis, characterized not only by increases in the
number and activity of lymphocytes and macrophages
but also by the numbers of resident mesenchymal cells,
known as fibroblast-like synovial cells (FLS) [1]. Located
in the synovial lining, FLS derived from RA appear to
change their phenotype to become hyperplastic and
invasive, like tumor cells [2]. Accumulating evidence
indicates that the transformation of rheumatoid arthritis
fibroblast-like synovial cells (RA-FLS) occurs as a result
of both defective apoptosis and excessive proliferation.
The folic acid antagonist methotrexate (MTX), which
is a potent, competitive inhibitor of dihydrofolate reduc-
tase, is the most widely used of the disease-modifying
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antirheumatic drugs (DMARDs) in the treatment of RA
[3, 4]. Compared with the 5000 mg/week dosage used in
the treatment of malignancy, once-weekly administration
of MTX at 7.5–25 mg produces optimal clinical out-
comes in RA [5]. According to previous studies, apart
from the anti-inflammatory effects, MTX suppresses the
proliferation of lymphocytes and macrophages but has no
effect on spontaneous proliferation of RA-FLS [6, 7]. Its
promotion of RA-FLS apoptosis is rather limited [8–11].
Autophagy is a survival strategy employed by cells
undergoing nutrient deprivation or other stresses.
Increasing evidence indicates that autophagy protects
various tumor cells from apoptosis induced by chemo-
therapy drugs, both in vivo and in vitro [12–14]. Never-
theless, extensive or persistent autophagy also produces
cell death. Thus, autophagy often serves as an adapter
between cell death and survival [15]. Compared with
osteoarthritis (OA), both enhanced autophagy in RA
synovial tissues and increased induction of autophagy in
RA-FLS were recently described [16, 17]. Autophagy
exerted protective effects in these studies. This raises a
question about the role of autophagy in the process of
MTX treatment of RA-FLS.
On the basis of the present study, we report that MTX
induced protective autophagy in RA-FLS and that inhib-




Synovial tissue specimens were obtained from seven
patients with OA and seven patients with RA during
joint replacement surgery (Department of Joint Surgery,
Hong Hui Hospital, Xi’an, China). This study was
approved by the human research ethics committee of
the Xi’an Hong Hui Hospital, and all patients fulfilled
the American College of Rheumatology criteria for
classification of RA. All patients provided informed
consent. Clinical data, laboratory examination results,
and patient medications are summarized in Table 1.
Reagents and antibodies
MTX and antibodies against microtubule-associated
protein 1 light chain 3 (anti-LC3) were purchased from
Sigma-Aldrich (St. Louis, MO, USA). Anti-β-actin anti-
bodies were purchased from Biosen (Beijing, China).
High mobility group box chromosomal protein 1
(HMGB1), anti-poly(ADP-ribose) polymerase (PARP),
anti-phosphorylated mammalian target of rapamycin
(anti-p-mTOR), and anti-mTOR antibodies were pur-
chased from Abcam (Cambridge, UK). Anti-Beclin-1,
anti-Akt, and anti-phosphorylated Akt (anti-phospho-
Akt; Ser473) antibodies were purchased from Cell
Signaling Technology (Danvers, MA, USA).
Cell culture and treatment
Synovial fibroblasts were isolated from synovial tissue
specimens obtained from patients with RA and patients
with OA. Cells were cultured as described elsewhere
[18] and used between passages 3 and 8 for all experi-
ments. The concentrations of MTX used in the different
experiments ranged from 0.01 μM to 1 μM, and the
culture periods ranged from 24 h to 96 h of continuous
exposure to MTX. On the basis of pharmacokinetic
analysis, the ingestion of a 20-mg tablet of MTX yields
plasma MTX concentrations of approximately 0.5 μM
after 1 h and of approximately 0.1 μM after 10 h [19].
Controls were treated with matched amounts of di-
methyl sulfoxide (DMSO); 0.1 μM of bafilomycin A1
(Sigma-Aldrich), which inhibits the fusion of autophago-
somes with lysosomes, was added to cell cultures for the
last 4 h of treatment.
Cell viability assay
Cell viability was measured using a 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.
The cells were seeded at 5 × 104 cells/well in 96-well
plates, incubated overnight, and then exposed to the
indicated concentrations of MTX for the indicated
times. Thereafter, 20 μl of MTT solution (5 mg/ml) was
added to each well, and the cells were incubated for
another 4 h at 37 °C. After removal of the culture
medium, the cells were lysed in 200 μl of DMSO, and
the optical density (OD) was measured at 570 nm
with a microplate reader (Thermo Fisher Scientific,
Waltham, MA, USA). The following formula was
used: cell viability = (OD of the experimental sample/
OD of the control group) × 100 %.
Table 1 Patient characteristics
Patient characteristics OA RA
Total number of patients 7 7
Age,a yr 68 (58–70) 61 (55–75)
Sex, n, female/male 2/5 5/2
CRP,b mg/L 2.72 (2.25) 17.75 (26.52)
RF,b IU/ml 9.16 (2.90) 102.31 (70.07)
Anti-CCP–positive, n 0/7 6/7
ESR,b mm/h 12.43 (6.55) 39 (15.12)





CRP C-reactive protein, ESR erythrocyte sedimentation rate, MTX methotrexate,
RF rheumatoid factor, CCP cyclic citrullinated peptide, NSAID nonsteroidal
anti-inflammatory drug, TWP Tripterygium wilfordii polyglycoside
aMedian (range)
bMean (standard error of the mean)
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Analysis of cell death
After treatment, cells were detached with trypsin, washed
twice with 1× phosphate-buffered saline (PBS), and resus-
pended in annexin V binding buffer (7SeaPharmTech,
Shanghai, China) at a concentration of 3 × 105 cells/ml.
Next, the cells were incubated with fluorescein isothio-
cyanate–annexin V (7SeaPharmTech) for 15 minutes at
room temperature in the dark and with propidium iodide
(7SeaPharmTech) for 5 minutes at 4 °C in the dark, and
then the cells were analyzed by flow cytometry (guava
easyCyte HT; EMD Millipore, Billerica, MA, USA).
Western blot analysis
Synovial fibroblasts and tissue specimens were washed
twice with ice-cold PBS and solubilized in Triton X-100
lysis buffer (50 mM Tris–HCl, pH 7.4, 150 mM NaCl,
0.2 mM ethylenediaminetetraacetic acid, 1 % Triton X-100,
1 % sodium deoxycholate, 0.1 % sodium dodecyl sulfate
[SDS]) and protease inhibitor cocktail (Beyotime, Shanghai,
China) on ice, then quantified using the Lowry method.
Cell lysate proteins (40 μg) were separated by SDS-
polyacrylamide gel electrophoresis and electrophoretically
transferred to nitrocellulose membranes (Immobilon-P;
EMD Millipore). The membranes were blocked in 5 %
skim milk in Tris-buffered saline with Tween 20 (TBST) at
room temperature for 1 h and incubated overnight at 4 °C
with the indicated primary antibodies. After a washing step
with TBST buffer, the membranes were reacted with the
appropriate horseradish peroxidase–conjugated secondary
antibodies for 1 h at room temperature. After incubation
with the secondary antibody, the membranes were washed
three times with TBST and developed via electroche-
miluminescence (Thermo Fisher Scientific) and using a
Western blotting detection system (GeneGnome 5;
Syngene, Cambridge, UK).
Transmission electron microscopy
After treatment, cells were detached with trypsin,
washed twice with PBS, and fixed in ice-cold 2 % glutar-
aldehyde/0.1 M phosphate buffer (pH 7.2), postfixed in
1 % osmium tetroxide, washed, dehydrated with a graded
ethanol series (30 %, 50 %, 70 %, 90 %, and 100 %), and
embedded in 1:1 propylene oxide/embedding resin. The
resin blocks were cut with a LKB V ultramicrotome
(LKB, Bromma, Sweden). Thin (60-nm) sections were
picked up on 200-mesh copper grids and stained with
uranyl acetate and lead citrate. The sections were exam-
ined with an H-7650 transmission electron microscope
(HITACHI, Ibaraki, Japan).
Transfection experiments
Both small interfering RNA (siRNA) targeting Beclin-1
complementary DNA (cDNA) sequence (5′-CAGTTTGG
CACAATCAATATT-3′) and HMGB1 cDNA sequence
(5′-CCCGTTATGAAAGAGAAATTT-3′) and a control
siRNA (5′-UUCUCCGAACGUGUCACGUTT-3′) were
obtained from Shanghai GenePharma (Shanghai, China).
Cells were transfected with either Beclin-1 siRNA or
control siRNA at 75 nmol/L using X-tremeGENE siRNA
transfection reagent (Roche Diagnostics, Mannheim,
Germany) according to the manufacturer’s guidelines.
Twenty-four hours after transfection, the cells were treated
as indicated and then harvested for Western blot analysis
or flow cytometry.
Statistical analysis
Mean ± SD values were calculated. According to whether
data are normally distributed, either the Mann–Whitney
U or Student’s t test was used for statistical evaluation of
the data (GraphPad Prism 5.0 software; GraphPad
Software, La Jolla, CA, USA). p Values less than 0.05
were considered significant.
Results
MTX inhibited cell viability and induced apoptosis
RA-FLS and osteoarthritis fibroblast-like synovial cells
(OA-FLS) were treated with MTX at concentrations
ranging from 0.01 μM to 10 μM for 48 h. By flow
cytometry, assayed the number of dead cells after treat-
ment with MTX, which showed that RA-FLS were more
resistant than OA-FLS to MTX-induced cell death
(Fig. 1a and b). Furthermore, cell viability assays showed
that MTX inhibited cell growth in a dose-dependent
manner (Fig. 1c). However, cell viability was 91.1 ± 2.5 %
even when treated with MTX at a concentration of
1 μM in RA-FLS, in contrast to 70.2 ± 8.2 % in OA-FLS.
MTX induced autophagosome formation
Both RA-FLS and OA-FLS were treated with MTX at
concentrations ranging from 0.01 μM to 10 μM for 48 h
and at times ranging from 12 h to 96 h at a concentra-
tion of 0.1 μM. An increase in type II LC3 (LC3-II) was
observed in both a dose-dependent a time-dependent
manner after treatment with MTX (Fig. 2a and b), indi-
cating the induction of autophagy. In addition, the in-
duction of autophagy was more pronounced in RA-FLS
than in OA-FLS (Fig. 2a and b).
The increase in LC3-II, which is indicative of auto-
phagy induction, reflects only the number of autopha-
gosomes formed; it provides no information about the
overall autophagic flux. Therefore, in this study, we
stimulated RA-FLS with MTX in the presence and ab-
sence of the lysosomal inhibitor bafilomycin A1 to block
the autophagic pathway at a late stage [20]. We showed
that MTX treatment also increased the autophagic flux
in RA-FLS, as demonstrated by an increased amount of
LC3-II in the presence of bafilomycin A1 (Fig. 2c).We
also detected the expression of P62 to confirm the
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autophagic flux, but no significant changes were found
(Additional file 1). The formation of autophagosomes
was further confirmed by transmission electron micros-
copy. Upon treatment with 0.1 μM MTX for 48 h, many
autophagic vesicles, double membrane–enclosed vesicles
containing engulfed organelles, were observed in the
cytoplasm of RA-FLS (Fig. 2d).
MTX-induced autophagy protected RA-FLS from
undergoing apoptosis
Because autophagy can result in both survival and cell
death in RA-FLS and OA-FLS, we next investigated
whether MTX-induced autophagy is protective or proa-
poptotic. In this experiment, we examined the role of
MTX-induced autophagy via knockdown of the autoph-
agy marker Beclin-1. Figure 3a shows that the levels of
Beclin-1 and LC3II were significantly decreased in
Beclin-1 siRNA-treated cells compared with the results
in siRNA controls. In RA-FLS, but not in OA-FLS, the
Beclin-1 siRNA significantly increased the apoptotic
population with 0.1 μM MTX (Fig. 3b). To further con-
firm that apoptosis was induced by MTX, Western blot-
ting was performed to detect the cleavage of PARP. As
shown in Fig. 3c, after 0.1 μM MTX treatment for 48 h,
the cleavage of PARP was increased more dramatically
in the RA-FLS transferred with Beclin-1 siRNA than
with the control siRNA, but it showed no comparable
change in OA-FLS transferred with Beclin-1 siRNA.
MTX induced autophagy through HMGB1 and Beclin-1,
not the Akt/mTOR pathway
To explore how MTX induces autophagy in RA-FLS and
OA-FLS treated with MTX at times ranging from 12 h
to 96 h at a concentration of 0.1 μM, two important
autophagy-related signaling pathways were investigated:
the Akt/mTOR signaling pathway and the HMGB1/
Fig. 1 Effects of methotrexate (MTX) on cell viability and apoptosis of osteoarthritis fibroblast-like synovial cells (OA-FLS) and rheumatoid arthritis
fibroblast-like synovial cells (RA-FLS). Cells were untreated or were treated with 0.01, 0.1, 1, or 10 μM MTX (a and b) for 48 h. The numbers of dead
cells were determined by flow cytometry following annexin V/propidium iodide (PI) staining. Cells were treated with 0.01, 0.1, 1, or 10 μM MTX
(c) for 48 h, and cell viability was analyzed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. The results are representative of
4 experiments using cells from different patients. Values in (b) and (c) are the mean ± standard deviation. The Mann–Whitney U test was chosen for
analysis of data from cell viability results of less than 0.01 μM MTX treatment in the MTT assay, while Student’s t test was used for the rest of the data.
*p < 0.05 vs. OA-FLS
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Beclin-1 pathway. As detected by Western blotting, the
levels of phospho-Akt and downstream p-mTOR were
more powerful in RA-FLS but were not affected by
prolonging the duration of MTX in both RA-FLS and
OA-FLS. Interestingly, the expression of HMGB1 and
Beclin-1 was upregulated in a time-dependent manner
in RA-FLS, but in OA-FLS it was very limited (Fig. 4a
and b). These data indicated that MTX-induced autophagy
might occur via upregulated HMGB1 and Beclin-1 rather
than through the Akt/mTOR signaling pathway in
RA-FLS.
Autophagy induction contributed to resistance to MTX
treatment in RA-FLS through HMGB1
We further confirmed the role of HMGB1 in MTX-
induced autophagy via knockdown of the expression of
Fig. 2 Determination of autophagy induction by monitoring the conversion of microtubule-associated protein 1 light chain 3 type I (LC3-I) to LC3-II in
whole protein extracts derived from osteoarthritis fibroblast-like synovial cells (OA-FLS) and rheumatoid arthritis fibroblast-like synovial cells (RA-FLS). Cells
were left untreated or were treated with 0.01, 0.1, 1, or 10 μM methotrexate (MTX) (a) for 48 h or 0.1 μM MTX (b) for the indicated times. Autophagic flux
was monitored in RA-FLS after 24 h of treatment with 0.1 μM MTX in the presence or absence of 0.1 μM bafilomycin A1 (Baf) (c). Cells were treated
with 0.1 μM MTX for 48 h (d), then harvested and subjected to transmission electron microscopy as described in the Methods section. The results are
representative of three experiments using cells from different patients. β-actin was used as a loading control in all experiments. Values in (a) and (b) are
the mean ± standard deviation. Student’s t test was used for the data analysis. *p < 0.05 vs. OA-FLS
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HMGB1. Figure 5a–c shows that the protein levels of
HMGB1 and LC3-II were significantly decreased in
HMGB1 siRNA-treated cells compared with the results
with the siRNA controls. In RA-FLS, the HMGB1 siRNA
significantly increased the apoptotic population com-
pared with the siRNA controls (Fig. 5d and e).
Discussion
A substantial increase in the number of RA-FLS, partly
but importantly resulting in synovial hyperplasia, is par-
tially caused by resistant apoptosis. Different from either
nonarthritic controls or patients with OA, RA-FLS
hardly show any signs of apoptosis, which was also ob-
served in animal model studies. Furthermore, RA-FLS
also exhibited resistance to apoptotic stimulation in a
number of in vitro studies. However, proliferation of
RA-FLS seems to contribute to synovial hyperplasia. It
has been reported in several research articles that some
cellular proliferation regulators, such as Ras and c-Myc,
are overexpressed in RA and that the inhibition of these
regulators can reduce the growth of RA-FLS both in
vitro and in vivo [21, 22].
One of the unique effects of MTX is the induction of
RA-FLS apoptosis, compared with other DMARDs,
which was first described by Nakazawa et al. [10]. Never-
theless, this effect was later shown to be compromised.
Terminal deoxynucleotidyl transferase deoxyuridine tri-
phosphate nick end labeling– and PARP-positive cells
were found mainly in the synovial lining macrophages,
but not in RA-FLS or other cell types, from RA synovial
biopsy specimens after MTX treatment [11]. Lee et al.
demonstrated apoptosis of RA-FLS treated with 100–
500 μM MTX in cell culture [9], which is a concentra-
tion that cannot be achieved in the plasma. In the
present study, we demonstrated a dose–effect relationship
between MTX and apoptosis of RA-FLS and OA-FLS.
However, apoptotic cells were detectable in the RA-FLS
(11.1 ± 0.9 %) cultured with MTX at a high dose of up to
Fig. 3 Inhibition of autophagy enhanced the proapoptotic effect of methotrexate (MTX) on osteoarthritis fibroblast-like synovial cells (OA-FLS)
and rheumatoid arthritis fibroblast-like synovial cells (RA-FLS). Cells were transfected with control or Beclin-1 small interfering RNA (siRNA),
followed by 0.1 μM MTX treatment for 48 h. The expression of Beclin-1 and microtubule-associated protein 1 light chain 3 types I and II (LC3-I
and LC3-II, respectively) was verified by Western blot analysis (a). The numbers of dead cells were determined by flow cytometry following
annexin V/propidium iodide (PI) staining (b). Verification of poly(ADP-ribose) polymerase (PARP) p85 protein expression by Western blot analysis
(c). The results are representative of four experiments using cells from different patients. β-actin was used as a loading control in all experiments.
Student’s t test was used for the data analysis. Values in (a) are the mean ± standard deviation (SD). *p < 0.05 vs. control siRNA. Values in (b) and
(c) are the mean ± SD. *p < 0.05 vs. OA-FLS transfected with control siRNA. #p < 0.05 vs. RA-FLS transfected with Beclin-1 siRNA
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1 μM, significantly less than OA-FLS (29.2 ± 2.2 %). In
contrast, pharmacokinetic analysis indicates that the in-
gestion of a 20-mg tablet of MTX yields plasma MTX
concentrations of approximately 0.5 μM after 1 h and
approximately 0.1 μM after 10 h.
Apart from the capacity of RA-FLS for apoptotic re-
sistance, advanced sensitivity to induced autophagy
seems to be another characteristic of RA-FLS that is in
contrast to OA-FLS [11, 16, 17, 23]; however, it is rarely
reported whether MTX has the ability to induce autoph-
agy in RA-FLS. In our study, the increased expression of
punctate LC3 and the morphologic changes were ob-
served among the cells treated with MTX. Western blot
analysis also showed that LC3-II expression was elevated
with MTX treatment in a dose-dependent and time-
dependent manner. If the increase in both LC3-II and
autophagosome occurs only as a result of either upregu-
lation of autophagosome formation or blockage of au-
tophagic degradation, autophagic flux would be detected
[24]. We found that in RA-FLS treated with 0.1 μM
MTX, LC3-II further accumulated in the presence of
bafilomycin A1, a lysosomal protease inhibitor. This
finding indicates enhancement of autophagic flux and
upregulated autophagosome formation by MTX [20]. To
our knowledge, this is the first report that MTX induces
autophagy in RA-FLS.
Autophagy has been shown to engage in a complex
interplay with cell survival. Sometimes it induces an
apoptotic or autophagic cell death accompanied by
massive cytoplasmic vacuolization; at other times, it
serves as a protector, as observed in RA-FLS. The
studies with patients with RA by Shin et al. demon-
strated that autophagy protects cells from death by
limiting the endoplasmic reticulum stress response in
fibroblasts [16]. However, a more recent study indicated
a different result. Autophagy induced by different stimuli
may lead to different and even opposite consequences.
Autophagy seems to play a dual role in the survival of
RA-FLS [23]. To clarify the consequences of autophagy
induced by MTX, we inhibited autophagic activity by
transferring Beclin-1 siRNA in RA-FLS, which sig-
nificantly decreased the Beclin-1 expression and sub-
sequently resulted in increased apoptosis with MTX
treatment. Under our experimental conditions, MTX-
induced autophagy served as a protector in RA-FLS.
The mTOR-dependent pathway is a classical regulator
of autophagy [25]. The target of rapamycin (TOR) kinase
is activated downstream of Akt kinase, phosphoinositide
3-kinase (PI3K), and growth factor receptor, signaling
when nutrients are available. Upstream of TOR, the
activation of adenosine 5′-monophosphate–activated
protein kinase in response to low ATP levels promotes
inhibitory activity of the Tsc1/Tsc2 tumor suppressor
proteins on Rheb, a small GTPase required for mTOR
activity. Reduced Akt activity in response to reduced
growth factor receptor activity also represses TOR
kinase through Tsc1 and Tsc2 [26, 27]. Thus, reduced TOR
activity induces autophagy. In this study, the expressions of
p-Akt and p-mTOR were higher in RA-FLS than in
OA-FLS, but these seemed irrelevant to the use of MTX.
Fig. 4 Effect of methotrexate (MTX) on autophagy-related proteins. a After the cells were exposed to 0.1 μM MTX for the indicated times, the cell
lysates were subjected to Western blotting with specific antibodies. The results are representative of three independent experiments. β-actin was
used as a loading control. b The levels of Akt, phosphorylated Akt (p-Akt), mammalian target of rapamycin (mTOR), phosphorylated mTOR (p-mTOR), high
mobility group box chromosomal protein 1 (HMGB1), Beclin-1, and microtubule-associated protein 1 light chain 3 (LC3) proteins were measured using
ImageJ software (National Institutes of Health, Bethesda, MD, USA) and corrected for β-actin. Data in columns represent mean of three independent
experiments, and values in (b) are the mean ± standard deviation. The Mann–Whitney U test was chosen for analysis of data for the levels of HMGB1
of cells exposed to 0.1 μM MTX for 48 h in Western blot assays, while Student’s t test was used for the rest of the data. *p < 0.05 vs. OA-FLS
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Autophagy induced under pathological conditions
functions as an adaptive cell response that allows the cell
to survive bioenergetic stress [28]. However, extensive or
persistent autophagy also results in cell death [29].
Bielen et al. found that phosphorylation of platelet-
derived growth factor receptor (PDGFR) α/β suppresses
autophagy by activating the PI3K/Akt/mTOR signaling
pathway, thereby preventing RA-FLS from undergoing
type II apoptosis induced by excessive autophagy and
leading to continuing proliferation of RA-FLS and aggra-
vation of the pathogenetic condition [30]. The activation
of the PI3K/Akt/mTOR signaling pathway may prevent
Fig. 5 Autophagy induction contributed to the resistance to methotrexate (MTX) treatment in rheumatoid arthritis fibroblast-like synovial cells
(RA-FLS) through high mobility group box chromosomal protein 1 (HMGB1). Cells were transfected with either HMGB1 small interfering RNA
(siRNA) or a nontarget control siRNA for 48 h, and the expression of microtubule-associated protein 1 light chain 3, types I and II (LC3 I and LC3
II, respectively) was verified by Western blotting (a, b, and c). The numbers of dead cells were determined by flow cytometry following annexin
V/propidium iodide (PI) staining (d and e). Data in columns represent the mean of three independent experiments, and values in (c) and (e) are
the mean ± standard deviation. The Mann–Whitney U test was chosen for analysis of data for the numbers of dead cells without MTX treatment,
while Student’s t test was used for the rest of the data. *p < 0.05 vs. control siRNA
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RA-FLS from excessive autophagy and avoid type II apop-
tosis. Therefore, this may be another survival mechanism
of drug treatment resistance. Nevertheless, why autoph-
agy is robust in RA-FLS after MTX treatment re-
mains unknown.
Fortunately, MTX induced in a time-dependent
manner the expression of Beclin-1 and HMGB1 in
RA-FLS, but this was very limited in OA-FLS. Beclin-
1, the mammalian homolog of the yeast Atg6, is a
key autophagy-promoting gene whose product is part
of a lipid kinase (class III PI3K [PtdIns3KC3]) com-
plex that participates in the early stages of autophago-
some formation [31]. Upregulated HMGB1 competes
with Bcl-2 to bind Beclin-1, which increases the for-
mation of the Beclin-1–PtdIns3KC3 complex and
stimulates autophagosome maturation and autophagy.
As an upstream signal, the activation of the ULK1–
mAtg13–FIP200 complex is required for the inter-
action between HMGB1 and Beclin-1 [32, 33]. We
also demonstrated that autophagy activity was down-
regulated after transferring HMGB1 siRNA. Therefore,
the robust autophagy of RA-FLS with MTX treatment
seems to be caused by HMGB1.
In addition, we found that the inhibition of HMGB1
increased the apoptotic population of RA-FLS after
MTX treatment. HMGB1 is an inducer of autophagy.
Our study showed that knockdown of HMGB1 de-
creased LC3-II levels and inhibited autophagy activity,
resulting in increased apoptosis, which is the same result
found in non–small cell lung cancer [34]. Apart from its
proautophagic effect and its interactions with receptor
for advanced glycation endproducts (RAGE) and Toll-
like receptor 4, HMGB1 plays a crucial role in various
inflammation processes [35]. The induction of HMGB1
may mediate proinflammatory action in RA-FLS, while
inhibition of the HMGB1–RAGE interaction may have
anti-inflammatory effects in RA [36, 37]. The inhibition
of the proinflammatory effects through the transfer of
HMGB1 siRNA may be another cause of the increased
drug sensitivity of RA-FLS. However, further study is re-
quired to explain how MTX induces the expression of
HMGB1 and Beclin-1.
Conclusions
The results of the present study suggest that RA-FLS
may use the autophagic pathway in which HMGB1
and Beclin-1 (but not the Akt/mTOR pathway) are
involved as a survival mechanism to evade the pertur-
bations of cellular biosynthetic processes by the anti-
metabolite MTX to sustain cell viability in conditions
of metabolic stress. Thus, a combination of MTX and
an autophagy inhibitor might be more effective for
the treatment of RA.
Additional file
Additional file 1: The expression of P62 in RA-FLS and OA-FLS treated
with 0.1μM MTX for the indicated times (TIF 698 kb)
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OA: osteoarthritis; OA-FLS: osteoarthritis fibroblast-like synovial cells; OD: optical
density; PBS: phosphate-buffered saline; PARP: poly(ADP-ribose) polymerase;
PI: propidium iodide; PI3K: phosphoinositide 3-kinase; p-mTOR: phosphorylated
mammalian target of rapamycin; PtdIns3KC3: class III phosphoinositide 3-kinase;
RA: rheumatoid arthritis; RA-FLS: rheumatoid arthritis fibroblast-like synovial cells;
RAGE: receptor for advanced glycation endproducts; RF: rheumatoid factor;
SD: standard deviation; SDS: sodium dodecyl sulfate; siRNA: small interfering
RNA; TBST: Tris-buffered saline with Tween 20; TOR: target of rapamycin;
TWP: Tripterygium wilfordii polyglycoside.
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